Changes in markers of t-cell senescence and exhaustion with atazanavir-, raltegravir-, and darunavir-based initial antiviral therapy: Actg 5260s

Theodoros Kelesidis; Carlee Moser; James H. Stein; Todd T. Brown; Thuy Tien T. Tran; Heather J. Ribaudo; Michael P. Dube; Otto O. Yang; Judith S. Currier; Grace A. McComsey

doi:10.1093/infdis/jiw253

Changes in markers of t-cell senescence and exhaustion with atazanavir-, raltegravir-, and darunavir-based initial antiviral therapy: Actg 5260s

Theodoros Kelesidis, Carlee Moser, James H. Stein, Todd T. Brown, Thuy Tien T. Tran, Heather J. Ribaudo, Michael P. Dube, Otto O. Yang, Judith S. Currier, Grace A. McComsey

School of Medicine

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

It is unclear whether differential roles of CD4<^>+< versus CD8+ T-cell senescence/exhaustion and effects of antiretroviral therapy (ART) on these processes may contribute to morbidity in treated human immunodeficiency virus type 1 (HIV) infection. In a prospective 96-week trial, 328 HIV-infected ART-naive participants were randomly assigned to receive tenofovir-emtricitabine plus either atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. Markers of CD4<^>+< T-cell senescence (ie, the percentage of CD28?CD57+ cells among CD4<^>+< T cells ) and CD4<^>+</CD8+ T-cell exhaustion (ie, the percentage of PD-1+ cells among CD4<^>+</CD8+ T cells) decreased after ART. There were no changes inmarkers of CD8+ T-cell senescence after ART and no differential changes in all markers in ART groups. Senescent CD4<^>+< and CD8+ T cells may have differential roles in HIV pathogenesis.

Original language	English (US)
Pages (from-to)	748-752
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	214
Issue number	5
DOIs	https://doi.org/10.1093/infdis/jiw253
State	Published - Sep 1 2016

Keywords

Antiretroviral therapy
Biomarkers
Human immunodeficiency virus
Immune activation
Inflammation

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

Access to Document

10.1093/infdis/jiw253

Cite this

Kelesidis, T., Moser, C., Stein, J. H., Brown, T. T., Tran, T. T. T., Ribaudo, H. J., Dube, M. P., Yang, O. O., Currier, J. S., & McComsey, G. A. (2016). Changes in markers of t-cell senescence and exhaustion with atazanavir-, raltegravir-, and darunavir-based initial antiviral therapy: Actg 5260s. Journal of Infectious Diseases, 214(5), 748-752. https://doi.org/10.1093/infdis/jiw253

Kelesidis, T, Moser, C, Stein, JH, Brown, TT, Tran, TTT, Ribaudo, HJ, Dube, MP, Yang, OO, Currier, JS & McComsey, GA 2016, 'Changes in markers of t-cell senescence and exhaustion with atazanavir-, raltegravir-, and darunavir-based initial antiviral therapy: Actg 5260s', Journal of Infectious Diseases, vol. 214, no. 5, pp. 748-752. https://doi.org/10.1093/infdis/jiw253

@article{2f917d409b714d2b90fd6b4ea7d19e0d,

title = "Changes in markers of t-cell senescence and exhaustion with atazanavir-, raltegravir-, and darunavir-based initial antiviral therapy: Actg 5260s",

abstract = "It is unclear whether differential roles of CD4<>+< versus CD8+ T-cell senescence/exhaustion and effects of antiretroviral therapy (ART) on these processes may contribute to morbidity in treated human immunodeficiency virus type 1 (HIV) infection. In a prospective 96-week trial, 328 HIV-infected ART-naive participants were randomly assigned to receive tenofovir-emtricitabine plus either atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. Markers of CD4<>+< T-cell senescence (ie, the percentage of CD28?CD57+ cells among CD4<>+< T cells ) and CD4<>+</CD8+ T-cell exhaustion (ie, the percentage of PD-1+ cells among CD4<>+</CD8+ T cells) decreased after ART. There were no changes inmarkers of CD8+ T-cell senescence after ART and no differential changes in all markers in ART groups. Senescent CD4<>+< and CD8+ T cells may have differential roles in HIV pathogenesis.",

keywords = "Antiretroviral therapy, Biomarkers, Human immunodeficiency virus, Immune activation, Inflammation",

author = "Theodoros Kelesidis and Carlee Moser and Stein, {James H.} and Brown, {Todd T.} and Tran, {Thuy Tien T.} and Ribaudo, {Heather J.} and Dube, {Michael P.} and Yang, {Otto O.} and Currier, {Judith S.} and McComsey, {Grace A.}",

note = "Funding Information: Financial port. This work was ported by the NIH (grants HL095132, HL095126, AI 068636, AI068634, AI69471, AI069501, and AI56933), Gilead, Merck, Bristol Myers Squibb (BMS), Janssen, and the National Institute of Allergy and Infectious Diseases (awards UM1 AI068634, UM1 AI068636, and UM1 AI106701). Publisher Copyright: {\textcopyright} The Author 2016.",

year = "2016",

month = sep,

day = "1",

doi = "10.1093/infdis/jiw253",

language = "English (US)",

volume = "214",

pages = "748--752",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Changes in markers of t-cell senescence and exhaustion with atazanavir-, raltegravir-, and darunavir-based initial antiviral therapy

T2 - Actg 5260s

AU - Kelesidis, Theodoros

AU - Moser, Carlee

AU - Stein, James H.

AU - Brown, Todd T.

AU - Tran, Thuy Tien T.

AU - Ribaudo, Heather J.

AU - Dube, Michael P.

AU - Yang, Otto O.

AU - Currier, Judith S.

AU - McComsey, Grace A.

N1 - Funding Information: Financial port. This work was ported by the NIH (grants HL095132, HL095126, AI 068636, AI068634, AI69471, AI069501, and AI56933), Gilead, Merck, Bristol Myers Squibb (BMS), Janssen, and the National Institute of Allergy and Infectious Diseases (awards UM1 AI068634, UM1 AI068636, and UM1 AI106701). Publisher Copyright: © The Author 2016.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - It is unclear whether differential roles of CD4<>+< versus CD8+ T-cell senescence/exhaustion and effects of antiretroviral therapy (ART) on these processes may contribute to morbidity in treated human immunodeficiency virus type 1 (HIV) infection. In a prospective 96-week trial, 328 HIV-infected ART-naive participants were randomly assigned to receive tenofovir-emtricitabine plus either atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. Markers of CD4<>+< T-cell senescence (ie, the percentage of CD28?CD57+ cells among CD4<>+< T cells ) and CD4<>+</CD8+ T-cell exhaustion (ie, the percentage of PD-1+ cells among CD4<>+</CD8+ T cells) decreased after ART. There were no changes inmarkers of CD8+ T-cell senescence after ART and no differential changes in all markers in ART groups. Senescent CD4<>+< and CD8+ T cells may have differential roles in HIV pathogenesis.

AB - It is unclear whether differential roles of CD4<>+< versus CD8+ T-cell senescence/exhaustion and effects of antiretroviral therapy (ART) on these processes may contribute to morbidity in treated human immunodeficiency virus type 1 (HIV) infection. In a prospective 96-week trial, 328 HIV-infected ART-naive participants were randomly assigned to receive tenofovir-emtricitabine plus either atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. Markers of CD4<>+< T-cell senescence (ie, the percentage of CD28?CD57+ cells among CD4<>+< T cells ) and CD4<>+</CD8+ T-cell exhaustion (ie, the percentage of PD-1+ cells among CD4<>+</CD8+ T cells) decreased after ART. There were no changes inmarkers of CD8+ T-cell senescence after ART and no differential changes in all markers in ART groups. Senescent CD4<>+< and CD8+ T cells may have differential roles in HIV pathogenesis.

KW - Antiretroviral therapy

KW - Biomarkers

KW - Human immunodeficiency virus

KW - Immune activation

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=84988946808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988946808&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiw253

DO - 10.1093/infdis/jiw253

M3 - Article

C2 - 27354367

AN - SCOPUS:84988946808

SN - 0022-1899

VL - 214

SP - 748

EP - 752

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 5

ER -

Changes in markers of t-cell senescence and exhaustion with atazanavir-, raltegravir-, and darunavir-based initial antiviral therapy: Actg 5260s

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this